title: [Expression of serum FSTL-1 in bone metastasis of prostate cancer and its clinical implication].
abstract: OBJECTIVE
  To investigate the expression of follistatin-like protein 1 (FSTL-1) in bone metastasis of prostate cancer (BMPC), the correlation of serum FSTL-1 with the chronic inflammatory factor interleukin-6 (IL-6) and bone morphogenetic protein 6 (BMP6) , and the clinical application value of serum FSTL-1 in BMPC.
  
  
  METHODS
  Using ELISA, we measured the expression levels of serum FSTL-1, IL-6, and BMP6 in 35 patients with BMPC and another 30 with benign prostatic hyperplasia (BPH) and performed correlation analysis on the data obtained.
  
  
  RESULTS
  Compared with the BPH controls, the BMPC patients showed a significantly decreased expression of serum FSTL-1 ([34.45 ± 12.35] μg/L vs [20.23 ± 8.69] μg/L, P < 0.01) and increased levels of IL-6 ([11.21 ± 8.62] μg/L vs [23.56 ± 20.12] μg/L, P < 0.05) and BMP6 ([293.50 ± 39.72] μg/L vs [428.30 ± 178.40] μg/L, P < 0.05). There was a significant negative correlation between the level of serum FSTL-1 and those of IL-6 and BMP6 in the BMPC patients, with correlation coefficients of -0.971 and -0.972, respectively (P < 0.05).
  
  
  CONCLUSIONS
  The expression of serum FSTL-1 decreases in patients with bone metastasis of prostate cancer, and it is correlated with the levels of inflammatory factor and cell transformation factor. This finding offers a novel biological marker for the development and progression of prostate cancer as well as a new biological target factor for its intervention.
authors.affiliation: Department of Urology, Third Hospital of Soochow University, Jiangsu, China. teito-72@sohu.com
authors.forename: Tao
authors.initials: T
authors.lastname: Ding
authors.forename: Xiao-Zhou
authors.initials: XZ
authors.lastname: He
authors.forename: Xian-Lin
authors.initials: XL
authors.lastname: Xu
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Xu
authors.forename: Cui-Xing
authors.initials: CX
authors.lastname: Zhou
authors.forename: Yu-Ji
authors.initials: YJ
authors.lastname: Wang
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D055418:Bone Morphogenetic Protein 6 / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood* / Q000556:secondary*; D018450:Disease Progression; D038702:Follistatin-Related Proteins / Q000097:blood*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; D055418:Bone Morphogenetic Protein 6; D038702:Follistatin-Related Proteins; D015850:Interleukin-6